医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

New Research on SINOVAC’s COVID-19 Vaccine Shows Third Dose More Effective Against COVID-19, Including the Delta Variant

2021年09月09日 PM07:00
このエントリーをはてなブックマークに追加


 

BEIJING

SINOVAC Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, announced a paper, titled “A third dose of inactivated vaccine augments the potency, breadth, and duration of anamnestic responses against SARS-CoV-2,” is available on medRxiv. The findings suggest a third dose of CoronaVac® can induce a better neutralization breadth to variants of concern (“VOCs”), including the Delta variant, a rapid immunological memory response, and a long-lasting humoral response. Having a third dose of inactivated COVID-19 vaccine is more effective for COVID-19 prevention.

This study includes an in-depth exploration of the immunogenic profiles of antibodies from three and two-dose CoronaVac® recipients and convalescents. The findings indicate that three-dose vaccinees demonstrated better neutralization breadth to VOCs, expeditious recall, and long-lasting humoral immune response. Analysis of 171 complex structures of neutralizing antibodies identified structure-activity correlation and revealed ultrapotent, VOCs-resistant, and broad-spectrum patches.

As part of this study, researchers also constructed immunogenic and mutational heat maps, which revealed a direct relationship between “hot” immunogenic sites and areas with high mutation frequencies. Prolonged and repeated antigen stimulation can induce ongoing antibody somatic mutation, memory B cell clonal turnover, and antigen composition changes in B cell repertoire, which result in the development of monoclonal antibodies with enhanced neutralizing potency and breadth.

The above research provides a theoretical basis for a third dose of inactivated COVID-19 vaccine.

About SINOVAC

SINOVAC Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases. SINOVAC’s product portfolio includes vaccines against COVID-19, enterovirus71 (EV71), hepatitis A and B, seasonal influenza, 23-Valent pneumococcal polysaccharide (“PPV”), H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), varicella, mumps and Poliomyelitis. SINOVAC’s COVID-19 vaccine, CoronaVac®, has been granted emergency use approval or conditional marketing authorization by over 50 countries or regions worldwide. Healive®, the hepatitis A vaccine manufactured by the Company, has passed the assessment under WHO prequalification procedures in 2017. The EV71 vaccine, an innovative vaccine developed by SINOVAC against hand foot and mouth disease caused by EV71, was commercialized in China in 2016. In 2009, SINOVAC was the first company worldwide to receive approval for its H1N1 influenza vaccine, which it has supplied to the Chinese Government’s vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine to the government stockpiling program. In 2021, SINOVAC’s Sabin-strain inactivated polio vaccine has approved for registration. The Company is developing several new products including combined vaccines. SINOVAC primarily sells its vaccines in China, while also exploring growth opportunities in international markets. The Company is seeking market authorization of its products in over 30 countries outside of China. For more information, please see the Company’s website at www.sinovac.com.

Safe Harbor Statement

This press release may include certain statements that are not descriptions of historical facts, but are forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar statements. Forward-looking statements involve risks, uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements. In particular, the outcome of any litigation is uncertain, and the Company cannot predict the potential results of the litigation it filed or filed against it by others. Additionally, the triggering of a shareholder rights plan is nearly unprecedented, and the Company cannot predict the impact on the Company or its stock price as a result of the trigger of the rights plan.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210909005437/en/

CONTACT

Sinovac Biotech Ltd.

Helen Yang

Tel: +86-10-8279-9871 or

+86-10-5693-1897

Fax: +86-10-6296-6910

Email: ir@sinovac.com

ICR Inc.

Bill Zima

U.S.: 1-646-308-1707

Email: william.zima@icrinc.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • DKT International Implements Traditional and New Forms of Marketing in Africa, South America, and Southeast Asia to Expand Access to Contraceptives
  • オルガノンが計画外妊娠をめぐり世界規模の対話の喚起を目指す
  • IHMA Opens Microbiology Reference Laboratory in Shanghai, China to Further Support Global Anti-Infective Product Discovery and Development
  • Cyclica and IMPACT Therapeutics Team Up to Advance Differentiated Anti-cancer Drug Development
  • Takeda Selects Four New Partners for Annual Global Corporate Social Responsibility (CSR) Program to Help Strengthen Health Systems in Low- and Middle-Income Countries